CIK 0001682852
- Large accelerated filer
Moderna, Inc.
Sign in to watch- Ticker
- MRNA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813467528
- Phone
- +1 617-714-6500
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- Moderna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $50,775,837
- in 5 filings, $50.8M under 10b5-1 plans
Net −$50,775,837. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-28 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −27,155 | 0 | ||
| 2023-06-28 | AFEYAN NOUBAR Director | Sale 10b5-1 | −1,700 | $119.84 | $204K | 2,125,509 |
| 2023-06-28 | AFEYAN NOUBAR Director | Sale 10b5-1 | −3,131 | $120.77 | $378K | 2,122,378 |
| 2023-06-28 | AFEYAN NOUBAR Director | Sale 10b5-1 | −8,073 | $121.87 | $984K | 2,114,305 |
| 2023-06-28 | AFEYAN NOUBAR Director | Sale 10b5-1 | −2,096 | $122.83 | $257K | 2,112,209 |
| 2023-06-22 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-06-22 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −24,829 | $119.13 | $3.0M | 5,427,117 |
| 2023-06-22 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −15,171 | $119.87 | $1.8M | 5,411,946 |
| 2023-06-22 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −40,000 | 27,155 | ||
| 2023-06-21 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-06-21 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −20,711 | $121.77 | $2.5M | 5,431,235 |
| 2023-06-21 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −19,289 | $122.21 | $2.4M | 5,411,946 |
| 2023-06-21 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −40,000 | 67,155 | ||
| 2023-06-21 | AFEYAN NOUBAR Director | Sale 10b5-1 | −7,810 | $121.60 | $950K | 2,134,399 |
| 2023-06-21 | AFEYAN NOUBAR Director | Sale 10b5-1 | −6,790 | $122.26 | $830K | 2,127,609 |
| 2023-06-21 | AFEYAN NOUBAR Director | Sale 10b5-1 | −400 | $123.48 | $49K | 2,127,209 |
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −4,788 | $125.61 | $601K | 5,447,158 |
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −5,377 | $127.01 | $683K | 5,441,781 |
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −8,443 | $127.99 | $1.1M | 5,433,338 |
Page 42 of 66 · 1,314 trades